Streetbeat News

QNRX

Quoin Pharmaceuticals, Ltd.

Industry

Biotechnology

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Open

0.29

Mkt cap

2.5M

Volume

329K

High

0.30

P/E Ratio

-0.16

52-wk high

1.57

Low

0.29

Div yield

N/A

52-wk low

0.27

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) provided a corporate update and reported its financial results for Q4 and full-year 2024. The company focuses on rare and orphan diseases.

Portfolio Pulse from

March 13, 2025 | 11:45 am

Quoin Pharmaceuticals has filed U.S. and international patent applications for new topical rapamycin formulations aimed at treating rare diseases such as microcystic lymphatic malformations and venous malformations. These formulations utilize Quoin's proprietary Invisicare delivery technology.

Portfolio Pulse from

March 04, 2025 | 12:45 pm

Quoin Pharmaceuticals announced positive clinical data from its ongoing study on Pediatric Netherton Syndrome, showing significant improvement in patients using QRX003 with no adverse events reported.

Portfolio Pulse from

February 27, 2025 | 12:45 pm

Quoin Pharmaceuticals has launched a video series titled 'NETHERTON NOW' to raise awareness about Netherton Syndrome. This initiative aims to educate the public and increase visibility for the condition.

Portfolio Pulse from

February 25, 2025 | 12:45 pm

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has released highly positive interim data from its Netherton Syndrome clinical trials, as highlighted in an interview with CEO Dr. Michael Myers by PRISM MarketView.

Portfolio Pulse from

January 07, 2025 | 7:45 pm

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has announced additional positive interim data from its ongoing clinical study on Netherton Syndrome, a rare and orphan disease.

Portfolio Pulse from

January 06, 2025 | 1:45 pm

Quoin Pharmaceuticals Ltd. has announced a $6.8 million public offering, involving 15,111,110 ordinary shares represented by ADSs and warrants, priced at $0.45 per ADS. The Series F and G warrants have a $0.45 exercise price, expiring in two and five years, respectively.

Portfolio Pulse from

December 20, 2024 | 2:30 pm

Quoin Pharmaceuticals has received FDA clearance to start a new clinical study for QRX003, a treatment for Netherton Syndrome. This marks a significant step for the company in addressing rare and orphan diseases.

Portfolio Pulse from

December 19, 2024 | 1:15 pm

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced positive interim data from two ongoing clinical studies focused on Netherton Syndrome, a rare and orphan disease.

Portfolio Pulse from

December 18, 2024 | 1:30 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. VSee Health (VSEE) saw a notable increase of 66.5%, while GRI Bio (GRI) rose by 21.58%. On the downside, SAB Biotherapeutics (SABS) fell by 7.8%, and Healthcare Triangle (HCTI) decreased by 7.21%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.